Telephone
61.3.8532.2700
Address
4-6 Southampton Crescent Abbotsford, Victoria (VIC) 3067
Description
Starpharma Holdings Ltd. engages in the research and development of dendrimer products for pharmaceutical, life science and other applications. The firm's programs include: VivaGel portfolio, Drug delivery and Agrochemicals, which develops a number of products internally and others via commercial partnerships. Its product VivaGel, a gel-based formulation of a proprietary dendrimer and is under clinical development for the treatment and prevention of bacterial vaginosis and also as a vaginal microbicide to prevent the transmission of sexually transmitted infections including HIV and genital herpes. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.12 - 0.7
Trade Value (12mth)
AU$34,017.00
1 week
0%
1 month
-3.57%
YTD
-74.53%
1 year
-75.23%
All time high
2.52
EPS 3 yr Growth
-3.000%
EBITDA Margin
-798.90%
Operating Cashflow
-$14m
Free Cash Flow Return
-29.00%
ROIC
-33.50%
Interest Coverage
N/A
Quick Ratio
3.10
Shares on Issue (Fully Dilluted)
410m
HALO Sector
Healthcare
Next Company Report Date
21-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.60
Date | Announcements |
---|---|
31 October 23 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
31 October 22 |
Change in Director's Interest Notice - J Fairley
×
Change in Director's Interest Notice - J Fairley |
31 October 22 |
Change in Director's Interest Notice - R Thomas
×
Change in Director's Interest Notice - R Thomas |
31 July 23 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
31 July 23 |
Partnered Program Update
×
Partnered Program Update |
31 January 23 |
Dr Russell Basser appointed as non-executive director
×
Dr Russell Basser appointed as non-executive director |
31 August 11 |
Starpharma presents at Macquarie investor event
×
Starpharma presents at Macquarie investor event |
30 September 22 |
2022 Annual General Meeting Date
×
2022 Annual General Meeting Date |
30 September 20 |
Investor Presentation
×
Investor Presentation |
30 September 09 |
Annual Report to shareholders
×
Annual Report to shareholders |
30 November 22 |
Retirement of non-executive Director
×
Retirement of non-executive Director |
30 November 21 |
AGM Chairman address and CEO presentation
×
AGM Chairman address and CEO presentation |
30 November 12 |
AGM Chair address and CEO presentation
×
AGM Chair address and CEO presentation |
30 June 22 |
VIRALEZE relaunched by LloydsPharmacy in the UK
×
VIRALEZE relaunched by LloydsPharmacy in the UK |
30 January 23 |
Quarterly Activities Report & Appendix 4C
×
Quarterly Activities Report & Appendix 4C |
30 August 16 |
Starpharma Highlights of FY2016 Presentation
×
Starpharma Highlights of FY2016 Presentation |
29 September 23 |
Ceasing to be a substantial holder
×
Ceasing to be a substantial holder |
29 September 08 |
Annual Report to shareholders
×
Annual Report to shareholders |
29 October 21 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
29 November 23 |
AGM Chairman's address and CEO presentation
×
AGM Chairman's address and CEO presentation |
29 November 23 |
AGM Results
×
AGM Results |
29 November 22 |
AGM Chairman address and CEO presentation
×
AGM Chairman address and CEO presentation |
29 November 22 |
AGM Results
×
AGM Results |
29 November 18 |
AGM - Chairman address and CEO presentation
×
AGM - Chairman address and CEO presentation |
29 November 17 |
AGM - Chairman address and CEO presentation
×
AGM - Chairman address and CEO presentation |
29 November 16 |
AGM - Chairman address and CEO presentation
×
AGM - Chairman address and CEO presentation |
29 May 19 |
Starpharma presents at UBS Healthcare Conference
×
Starpharma presents at UBS Healthcare Conference |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.